Financial Data and Key Metrics Changes - The company's total revenue for 2025 was RMB 82.24 billion, a year-on-year decrease of 7.3, which was in line with expectations. Sales volume fell by around 4%, while the average selling price declined by around 3% [3][4] - The gross profit margin reached a record high of 39.9%, an increase of 0.3 percentage points from 39.6% in 2024. Operating profit was RMB 6.56 billion, with an operating profit margin of 8.0%, a slight decrease of 0.2 percentage points year-on-year [4] - Adjusted profit attributable to owners was RMB 3.96 billion, excluding non-recurring impairments [4] Business Line Data and Key Metrics Changes - The liquid milk business faced pressure overall in 2025, but the second half showed signs of stabilization and improvement. Segments such as fresh milk, infant milk formula, and adult milk formula achieved double-digit growth, with cheese growth exceeding 20% [5][6] - Selling expenses fell by 6.5% to RMB 21.59 billion, but the selling expense ratio and administrative expenses ratio rose slightly due to negative operating leverage [6] - The fresh milk business achieved double-digit growth, with market share increasing further, while the ice cream business also saw double-digit growth with improved profitability [15][16] Market Data and Key Metrics Changes - Mengniu maintained its position as the top market leader in the chilled sector for 21 consecutive years, with significant growth in the cheese segment, particularly in Southeast Asia [12][17] - The company reported strong growth in the Southeast Asian market, especially in Vietnam, with sales doubling within the year [19] Company Strategy and Development Direction - Mengniu is focusing on creating long-term value for consumers rather than engaging in low-price competition. The company aims to enhance its cash generation capabilities and increase shareholder returns through a three-year shareholder return plan [8][9] - The company is committed to digital intelligence transformation, R&D innovation, channel upgrading, and brand-led strategies to lead the industry into a new cycle of high-quality development [24][25] - Mengniu is expanding its product portfolio to include high-quality protein products and specialized medical foods, addressing diverse consumer needs [30][28] Management's Comments on Operating Environment and Future Outlook - The management noted that the dairy industry is benefiting from policy and market factors, with a clear trend towards recovery. China's per capita milk consumption is significantly lower than the global average, indicating substantial growth potential [22][23] - The company believes that the dairy industry remains a sector full of imagination and worth investing in, with opportunities for growth in functional and solid dairy products [24][27] Other Important Information - Mengniu has made solid progress on key ESG issues, being recognized in sustainability indices and maintaining an AA level MSCI ESG rating [21] - The company is enhancing its presence in lower-tier markets and expanding its omni-channel operational capabilities [12][31] Q&A Session Summary Question: What are the growth prospects for Mengniu in the coming years? - The management highlighted that the dairy industry is stabilizing and recovering, with significant growth potential in functional nutrition as China's per capita GDP has crossed the $13,000 threshold, indicating a period of explosive growth for the functional nutrition market [27][24] Question: How is Mengniu addressing the challenges in the liquid milk business? - The company is focusing on innovation and product diversification to navigate challenges, with signs of stabilization in the second half of 2025 [5][6]

Financial Data and Key Metrics Changes - The company's total revenue for 2025 was RMB 82.24 billion, a year-on-year decrease of 7.3%, which was in line with expectations. Sales volume fell by around 4%, while the average selling price declined by around 3% [3][4] - The gross profit margin reached a record high of 39.9%, an increase of 0.3 percentage points from 39.6% in 2024. Operating profit was RMB 6.56 billion, with an operating profit margin of 8.0%, a slight decrease of 0.2 percentage points year-on-year [4] - Adjusted profit attributable to owners was RMB 3.96 billion, excluding non-recurring impairments [4] Business Line Data and Key Metrics Changes - The liquid milk business faced pressure, but the second half of 2025 showed signs of stabilization. Segments such as fresh milk, infant milk formula, and adult milk formula achieved double-digit growth, with cheese growth exceeding 20% [5][6] - Selling expenses fell by 6.5% to RMB 21.59 billion, but the selling expense ratio and administrative expenses ratio rose slightly due to negative operating leverage [6] - The fresh milk business achieved double-digit growth, with market share increasing further, while the ice cream business also saw double-digit growth in 2025 [15][16] Market Data and Key Metrics Changes - Mengniu maintained its position as the top market leader in the chilled sector for 21 consecutive years, with significant growth in the cheese segment, particularly in Southeast Asia [12][17] - The company experienced strong growth momentum in the Southeast Asian market, especially in Vietnam, with sales doubling within the year [19][20] Company Strategy and Development Direction - Mengniu is focusing on innovation and high-quality development, steering clear of low-price competition. The company aims to create long-term value for consumers and enhance its cash generation capabilities [5][8] - The company has formulated a three-year shareholder return plan, increasing dividends per share and maintaining share buyback pace [9] - Mengniu's strategy includes enhancing digital intelligence transformation, R&D innovation, channel upgrading, and brand-led initiatives to lead the industry into a new cycle of high-quality development [24][25] Management's Comments on Operating Environment and Future Outlook - The dairy industry is expected to benefit from policy and market factors, with a clear trend towards recovery. China's per capita milk consumption is significantly lower than the global average, indicating substantial growth potential [22][23] - The company believes that the dairy industry remains a sector full of imagination and worth investing in, with opportunities presented by favorable policy environments and industry recovery [24][27] Other Important Information - Mengniu has made solid progress on key ESG issues, being recognized in various sustainability indices and maintaining an AA rating from MSCI [21] - The company is committed to advancing its sustainability strategy and creating social value through industrial value [21] Q&A Session Summary Question: What are the growth prospects for Mengniu in the coming years? - Mengniu anticipates that the dairy industry will stabilize and recover, with significant growth potential due to low per capita milk consumption in China compared to global averages [22][23] Question: How is Mengniu addressing the challenges in the liquid milk business? - The company is focusing on innovation and product diversification to navigate economic cycles and enhance resilience, with signs of stabilization in the second half of 2025 [5][6]

Financial Targets (2025-2028) - The company projects a constant currency (CC) revenue compound annual growth rate (CAGR) of 5-7% from 2025 to 2028[15, 42] - The company anticipates an adjusted EBITDA margin (excluding Acquired IPR&D) of approximately 23% in 2028[15, 42] - The company aims for an adjusted cash flow from operations to adjusted EBITDA conversion of approximately 50% in 2028[37, 42] - The company targets a net leverage ratio of approximately 3.5x by the end of 2028[37, 42] - The company expects double-digit adjusted EPS growth from 2026 to 2028[37, 42] Pipeline and Product Launches - The company's pipeline products have potential peak sales of approximately $7 billion[15] - The company anticipates franchise peak sales of approximately $300 million for an advanced preservative-free lipid-based formulation launching in the first half of 2026[23] - The company anticipates franchise peak sales of approximately $600 million for products expanding the market by addressing all stages of AMD, launching in the first half of 2026[23] - The company anticipates franchise peak sales of approximately $450 million for enhanced comfort contact lens with the addition of hyaluronic acid, launching in 1H27[23] Consumer Brands - The company is the 1 global OTC eye health company with +7% last twelve months (LTM) constant currency revenue growth[22]

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 was reported at $70 million, a decrease from $85 million in Q3 2024 [23][25] - The company recorded a net loss of $202 million, or $1.25 per diluted share, for the third quarter of 2025 [27] - Cash and accounts receivable at the end of Q3 2025 stood at $812 million, prior to factoring in additional earnings from recent transactions [25] Business Line Data and Key Metrics Changes - Product sales for Q3 2025 amounted to $13 million, primarily from COVID-19 vaccine and Matrix-M supply sales [25] - Licensing royalties and other revenue reached $57 million, mainly from the Sanofi agreement, including $46 million in R&D reimbursement [26] Market Data and Key Metrics Changes - Sanofi recorded $23 million in Nuvaxovid sales in Q3 2025, with Novavax earning $4 million in royalties from these sales [23][25] - The company anticipates a significant increase in royalties from Sanofi in 2026 as they prepare for a full commercial launch [32] Company Strategy and Development Direction - The company is transitioning from a focus on COVID-19 vaccine sales to a diversified pipeline and partnerships, aiming for long-term growth and profitability [5][7] - Key priorities for 2025 include optimizing the partnership with Sanofi, enhancing existing partnerships, and advancing the technology platform and early-stage pipeline [10][36] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about achieving non-GAAP profitability as early as 2028, contingent on successful partnerships and product developments [10][54] - The company is focused on reducing costs and improving financial strength while navigating a transition year with Sanofi [24][54] Other Important Information - The company has secured $1.4 billion in new cash while reducing its cost structure and liabilities, with 78% of this cash coming from non-dilutive sources [30] - A significant milestone of $225 million from Sanofi has been achieved, consistent with the 2025 revenue framework [25][30] Q&A Session Summary Question: How does the company see the 2025 COVID season compared to last year? - Management noted a 20% decrease in prescriptions compared to last year, attributing this to a more restrictive policy in the U.S. [41] Question: Can you provide more details on the BARDA grant? - The BARDA grant awarded to Sanofi is for early-stage work on a pandemic influenza vaccine that includes Novavax's Matrix-M adjuvant [43] Question: What are the next steps for the Sanofi collaboration? - Management is excited about the positive data from Sanofi's combination programs and is awaiting further updates on regulatory engagement [46] Question: What is the clinical bar for success for the shingles vaccine? - The company is confident in its data and is conducting experiments with positive controls to ensure comparability with existing vaccines [74][75]